(Q43674711)

25 November 2017

title

Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes (English)

1 reference

25 November 2017

1 reference

4

1 reference

25 November 2017

6

Ahrén B

1 reference

25 November 2017

3

Hellström PM

1 reference

25 November 2017

Gutniak MK

1

1 reference

25 November 2017

Svartberg J

series ordinal

2

1 reference

25 November 2017

Adner N

series ordinal

5

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

Journal of Internal Medicine

25 November 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

25 November 2017

volume

250

1 reference

25 November 2017

issue

1

1 reference

25 November 2017

page(s)

81-87

1 reference

Glucagon-like peptide-1 7-36: a physiological incretin in man.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Determination of free and total insulin and C-peptide in insulin-treated diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Glucagon-like peptide-1(7-36)-amide confers glucose sensitivity to previously glucose-incompetent beta-cells in diabetic rats: in vivo and in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00862.X

10.1046/J.1365-2796.2001.00862.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference